Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance01:07

Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance

26
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
26

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prolonged antibiotic treatment durations for community-onset infections in Dutch hospitals.

Antimicrobial stewardship & healthcare epidemiology : ASHE·2026
Same author

Performance of ChatGPT on Factual Knowledge Questions Regarding Clinical Pharmacy.

Journal of clinical pharmacology·2024
Same author

Poor performance of ChatGPT in clinical rule-guided dose interventions in hospitalized patients with renal dysfunction.

European journal of clinical pharmacology·2024
Same author

Documentation of the Patient Characteristics Morbid Obesity and Bariatric Surgery in the Hospital Information System and the Influence on the Number of Medication-Related Problems.

The Annals of pharmacotherapy·2024
Same author

Clinical Guidance for Dosing and Monitoring Oral Antihormonal Drugs in Patients with Breast Cancer After Roux-en-Y Gastric Bypass.

Therapeutic drug monitoring·2023
Same author

Assessment of drug-related problems at the emergency department in older patients living with frailty: pharmacist-led medication reviews within a geriatric care team.

BMC geriatrics·2023

Related Experiment Video

Updated: May 31, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.3K

Palbociclib Is Safe for Breast Cancer Patients With Mild Hepatic Impairment: A Multicenter Retrospective Study Using

Alieke K Bos1, Annelieke E C A B Willemsen2, Loes E Visser3,4

  • 1Department of Clinical Pharmacy, Tergooi Medical Centre, Hilversum, The Netherlands.

Clinical Pharmacology and Therapeutics
|January 24, 2025
PubMed
Summary

Mild hepatic impairment does not increase the risk of neutropenia or disease progression in breast cancer patients treated with palbociclib. Real-world data shows similar outcomes for patients with normal and mild liver dysfunction, guiding clinical decisions.

More Related Videos

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.1K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

378

Related Experiment Videos

Last Updated: May 31, 2025

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro
11:06

Human Liver Microphysiological System for Assessing Drug-Induced Liver Toxicity In Vitro

Published on: January 31, 2022

4.3K
A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma
12:24

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

5.1K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

378

Area of Science:

  • Oncology
  • Pharmacology
  • Hepatology

Background:

  • The liver is vital for metabolizing palbociclib, an anticancer drug.
  • Limited real-world data exists on hepatic impairment's effect on palbociclib toxicity and efficacy.
  • Understanding these effects is crucial for treating breast cancer patients with liver dysfunction.

Purpose of the Study:

  • To evaluate the impact of mild hepatic impairment on hematological toxicity and progression-free survival (PFS) in breast cancer patients receiving palbociclib.
  • To compare outcomes between patients with normal and mild hepatic function using real-world data.
  • To provide evidence-based guidance for palbociclib treatment in patients with mild liver impairment.

Main Methods:

  • A multicenter retrospective observational study of 478 female patients treated with palbociclib (August 2017 - February 2024).
  • Patients were categorized into normal and mild hepatic function groups based on the National Cancer Institute scoring system.
  • Regression analysis was used to compare the risk of grade 3/4 hematological toxicity and PFS between the groups.

Main Results:

  • Patients with mild hepatic impairment (n=205) showed no increased risk of grade 3/4 neutropenia compared to those with normal hepatic function (n=273) (HR=1.11; 95% CI 0.83-1.47).
  • Progression-free survival (PFS) was not significantly different between the mild hepatic impairment and normal hepatic function groups (HR=1.15; 95% CI 0.93-1.42).
  • Real-world data indicates comparable safety and efficacy of palbociclib in patients with mild hepatic impairment versus normal hepatic function.

Conclusions:

  • Mild hepatic impairment does not elevate the risk of palbociclib-induced neutropenia in breast cancer patients.
  • Palbociclib treatment in patients with mild hepatic impairment demonstrates similar progression-free survival compared to those with normal liver function.
  • These findings support the use of palbociclib in breast cancer patients with mild hepatic impairment, informing clinical practice.